title: Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis.
abstract: OBJECTIVE
  Eosinophilic esophagitis (EE) is a recently recognized clinical disorder that is understood poorly. We aimed to determine the efficacy of swallowed fluticasone propionate on the immunopathologic features associated with EE.
  
  
  METHODS
  A retrospective analysis was performed on 20 pediatric patients with EE. Inclusion criteria specified a peak eosinophil density of > or =24 cells per 400x field in the esophagus and treatment with swallowed fluticasone between 2 endoscopic assessments. Histologic specimens were examined for eosinophil and CD8(+) lymphocyte infiltration, papillary lengthening, and proliferation of the basal layer as determined by monoclonal anti-Ki-67 (MIB-1) antibody staining.
  
  
  RESULTS
  The mean time interval between endoscopic assessments was 4.8 months. The patients were divided equally between allergic and nonallergic groups based on the results of skin-prick testing. All of the nonallergic patients responded to fluticasone propionate. The endoscopic appearance of the mucosa improved and microscopic evaluation showed markedly reduced eosinophil infiltration, reduced basal layer hyperplasia documented by a reduced number of MIB-1(+) cells, and a reduced number of CD8(+) lymphocytes. However, allergic patients were relatively refractory to therapy; 20% had a partial response, whereas 20% had no detectable improvement. Esophageal eosinophil levels before and after therapy in all patients strongly correlated with the level of epithelial cell proliferation as measured by MIB-1 staining.
  
  
  CONCLUSIONS
  Collectively, these results suggest that patients treated with swallowed fluticasone have improved endoscopic, histologic, and immunologic parameters associated with EE. However, patients with identifiable allergies who fail dietary elimination may have a blunted response to treatment.
authors.affiliation: Department of Pediatrics, Cincinnati Children's Medical Center, Universityof Cincinnati College of Medicine, OH 45229-3039, USA. Rothenberg@cchmc.org
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Noel
authors.forename: Philip E
authors.initials: PE
authors.lastname: Putnam
authors.forename: Margaret H
authors.initials: MH
authors.lastname: Collins
authors.forename: Amal H
authors.initials: AH
authors.lastname: Assa'ad
authors.forename: Jesus R
authors.initials: JR
authors.lastname: Guajardo
authors.forename: Sean C
authors.initials: SC
authors.lastname: Jameson
authors.forename: Marc E
authors.initials: ME
authors.lastname: Rothenberg
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001707:Biopsy, Needle; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D004941:Esophagitis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D004945:Esophagoscopy; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone